A director at Quest Diagnostics Inc sold 1,748 shares at 175.515USD and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...
S&P 500 and Nasdaq 100 Testing Prior 2022 Highs Since late-February (2/25/25 Compass) we expected an 8-10% pullback to provide a buying opportunity. But that all changed in last week's Compass (4/1/25), when we downgraded our outlook to bearish/cautious, citing several concerning developments (SPX and QQQ failure at 200-day MAs, bear flag breakdowns across major indexes targeting 5100-5200 on SPX, high yield spreads widening above 355bps, major tops on market leaders NVDA and META, semiconducto...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of Quest Diagnostics Incorporated and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 3 April 2025 in which we reassessed the appropriateness of the ratings in th...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Moody's Ratings (Moodys) assigned a Baa1 rating to Quest Diagnostics Incorporated' ("Quest") proposed offering of senior unsecured notes. Quest intends to use the net proceeds from this offering to fund the recently announced acquisition of LifeLabs (a Canadian provider of community laboratory tests...
Moody's Ratings (Moody's) upgraded the senior unsecured debt ratings of Quest Diagnostics Incorporated ("Quest") to Baa1 from Baa2. Moody's also upgraded the rating on the company's senior unsecured shelf registration to (P)Baa1 from (P) Baa2. The outlook was changed to stable from positive. ...
Moody's Investors Service ("Moody's") assigned a Baa2 rating to the proposed offering of senior unsecured notes of Quest Diagnostics Incorporated ("Quest"). There are no changes to Moody's existing ratings of Quest including the Baa2 senior unsecured long-term ratings. The outlook remains unchanged ...
Moody's Investors Service ("Moody's") affirmed the senior unsecured ratings of Quest Diagnostics Incorporated ("Quest") at Baa2. At the same time, Moody's revised the outlook to positive from stable. The revision in outlook to positive reflects Moody's expectation for solid operating performance w...
The independent financial analyst theScreener just requalified the general evaluation of QUEST DIAGNOSTICS (US), active in the Health Care Providers industry. As regards its fundamental valuation, the title still shows 1 out of 4 stars and its market behaviour is seen as defensive. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Neutral. As of the analysis date January 14, 2022, the closing...
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Quest Diagnostics Incorporated. Global Credit Research- 14 Dec 2021. New York, December 14, 2021-- Moody's Investors Service has completed a periodic review of the ratings of Quest Diagnostics Incorporated and other ratings that are associated with the same analytical unit.
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Quest Diagnostics Incorporated. Global Credit Research- 03 Feb 2021. New York, February 03, 2021-- Moody's Investors Service has completed a periodic review of the ratings of Quest Diagnostics Incorporated and other ratings that are associated with the same analytical unit.
Summary Marketline's Exagen Diagnostics, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Exagen Diagnostics, Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of...
Summary Marketline's Clarient Diagnostic Services, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Clarient Diagnostic Services, Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a compre...
Rating Action: Moody's assigns Baa2 rating to Quest Diagnostics' notes offering. Global Credit Research- 11 May 2020. New York, May 11, 2020-- Moody's Investors Service, assigned a Baa2 rating to the proposed offering of senior unsecured notes of Quest Diagnostics Incorporated.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.